Epizyme, Inc. (EPZM) News
Filter EPZM News Items
EPZM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EPZM News Highlights
- EPZM's 30 day story count now stands at 6.
- Over the past 15 days, the trend for EPZM's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- APTX, BEAT and RAMP are the most mentioned tickers in articles about EPZM.
Latest EPZM News From Around the Web
Below are the latest news stories about EPIZYME INC that investors may wish to consider to help them evaluate EPZM as an investment opportunity.
Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet GoalAptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline |
Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/YEpizyme (EPZM) posts a narrower-than-expected loss in the second quarter. Revenues beat estimates. |
The past five years for Epizyme (NASDAQ:EPZM) investors has not been profitableEpizyme, Inc. ( NASDAQ:EPZM ) shareholders will doubtless be very grateful to see the share price up 219% in the last... |
Epizyme (EPZM) Reports Q2 Loss, Tops Revenue EstimatesEpizyme (EPZM) delivered earnings and revenue surprises of 41.67% and 172.20%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock? |
Epizyme Reports Second Quarter 2022 Financial Results and Provides Business UpdateCAMBRIDGE, Mass., August 09, 2022--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today reported second quarter 2022 financial results and provided a business update. |
Mass. M&A activity picks up among life sciences firmsMergers and acquisitions are starting to ramp up in Massachusetts' life sciences sector, but analysts believe the biggest buys are still yet to come. |
Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & MoreRegulatory and other updates from Epizyme (MRNA) and Kezar (KZR) are a few key highlights from the biotech sector during the past week. |
Epizyme shares soar 60% on acquisition newsFrench drugmaker Ipsen SA, which four years ago moved its U.S. headquarters to Cambridge, is snapping up the embattled cancer firm Epizyme Inc. for $247 million. Ipsen is paying $1.45 for each share of Epizyme (Nasdaq: EPZM), a 56% premium over where they were at market close on Friday. The company has a market capitalization of $246.5 million. |
Why Epizyme Stock Is Soaring TodayShares of the commercial-stage cancer company Epizyme (NASDAQ: EPZM) are soaring today. Epizyme's shares are racing higher today in response to a buyout agreement with French biopharma Ipsen (OTC: IPSEY). Ipsen reportedly agreed to pay $1.45 per share, as well as a milestone-dependent contingent value right (CVR) of $1.00 per share, to acquire the small-cap drugmaker. |
Epizyme (EPZM) Stock Surges on Acquisition Offer From IpsenIpsen, through its wholly-owned subsidiary, is set to acquire Epizyme (EPZM) for $1.45 per share, in cash, along with a contingent value right of $1 per share. The transaction is likely to close by third-quarter 2022. |